


PHARMACEUTICAL 2023









PHARMACEUTICAL 2023



Viracta Therapeutics Inc. Rank 111 of 446



The relative strengths and weaknesses of Viracta Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Viracta Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 101% points. The greatest weakness of Viracta Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 26% points.

The company's Economic Capital Ratio, given in the ranking table, is 186%, being 143% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	93,747
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	10,011
Liabilities, Non-Current	0
Other Assets	2,096
Other Compr. Net Income	-178
Other Expenses	0
Other Liabilities	0
Other Net Income	1,392
Other Revenues	0
Property and Equipment	148
Research and Development	26,262
Selling, General and Administrative Expense	24,327

Output Variable	Value in 1000 USD
Assets	95,991
Liabilities	10,011
Expenses	50,589
Revenues	0
Stockholders Equity	85,980
Net Income	-49,197
Comprehensive Net Income	-49,286
Economic Capital Ratio	186%

